Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S. Larkin J, et al. Among authors: valpione s. Cell Rep Med. 2024 Mar 19;5(3):101435. doi: 10.1016/j.xcrm.2024.101435. Epub 2024 Feb 27. Cell Rep Med. 2024. PMID: 38417447 Free PMC article. Clinical Trial.
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Kennedy OJ, et al. Among authors: valpione s. Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1. Eur J Cancer. 2024. PMID: 38402687 Clinical Trial.
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
Björk JR, Bolte LA, Maltez Thomas A, Lee KA, Rossi N, Wind TT, Smit LM, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Spector TD, Bataille V, Segata N, Hospers GAP, Weersma RK. Björk JR, et al. Among authors: valpione s. Nat Med. 2024 Mar;30(3):785-796. doi: 10.1038/s41591-024-02803-3. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365950 Free PMC article.
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Kennedy OJ, et al. Among authors: valpione s. Eur J Cancer. 2023 Aug;189:112900. doi: 10.1016/j.ejca.2023.04.016. Epub 2023 Apr 29. Eur J Cancer. 2023. PMID: 37277264 Clinical Trial.
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma.
Campana LG, Farronato S, Hodgetts J, Odili J, Vecchiato A, Bracken A, Baier S, Bechara FG, Borgognoni L, Caracò C, Carvalhal S, Covarelli P, Clover J, Eisendle K, Fantini F, Fierro MT, Farricha V, Gregorelli C, Hafner J, Kunte C, Gerlini G, Hessam S, Mandalà M, Piazzalunga D, Quaglino P, Snoj M, Ross AM, Trigona B, Moreno-Ramirez D, Tauceri F, Peach H, Rutkowski P, Muir T, de Terlizzi F, Patuzzo R, Mühlstädt M, Dietrich KA, Mussack T, Matteucci P, Kis E, Ascierto P, Sersa G, Valpione S; Melanoma Delphi Working Group. Campana LG, et al. Among authors: valpione s. Br J Surg. 2023 Jun 12;110(7):818-830. doi: 10.1093/bjs/znad105. Br J Surg. 2023. PMID: 37131298
T-Cell Infiltration and Clonality May Identify Distinct Survival Groups in Colorectal Cancer: Development and Validation of a Prognostic Model Based on The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Campana LG, Mansoor W, Hill J, Macutkiewicz C, Curran F, Donnelly D, Hornung B, Charleston P, Bristow R, Lord GM, Valpione S. Campana LG, et al. Among authors: valpione s. Cancers (Basel). 2022 Nov 29;14(23):5883. doi: 10.3390/cancers14235883. Cancers (Basel). 2022. PMID: 36497365 Free PMC article.
Tumour infiltrating B cells discriminate checkpoint blockade-induced responses.
Valpione S, Campana LG, Weightman J, Salih Z, Galvani E, Mundra PA, De Rosa F, Gupta A, Serra-Bellver P, Lorigan P, Germetaki T, Dynowski M, Kitcatt S, Sahoo S, Lee D, Dhomen N, Lord G, Marais R. Valpione S, et al. Eur J Cancer. 2022 Dec;177:164-174. doi: 10.1016/j.ejca.2022.09.022. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36347135 Free article.
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Lee KA, et al. Among authors: valpione s. Nat Med. 2022 Mar;28(3):535-544. doi: 10.1038/s41591-022-01695-5. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228751 Free PMC article.
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Kennedy OJ, et al. Among authors: valpione s. Eur J Cancer. 2022 Apr;165:97-112. doi: 10.1016/j.ejca.2022.01.017. Epub 2022 Feb 24. Eur J Cancer. 2022. PMID: 35220182 Free article. Clinical Trial.
T cell immune awakening in response to immunotherapy is age-dependent.
Salih Z, Banyard A, Tweedy J, Galvani E, Middlehurst P, Mills S, Weightman J, Gupta A, Lorigan PC, Zhou C, Dhomen N, Valpione S, Marais R. Salih Z, et al. Among authors: valpione s. Eur J Cancer. 2022 Feb;162:11-21. doi: 10.1016/j.ejca.2021.11.015. Epub 2021 Dec 21. Eur J Cancer. 2022. PMID: 34952479 Free PMC article.
60 results